The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma
Abstract
BACKGROUND: Adjuvant chemotherapy has been suggested as a possible strategy to improve survival in women with early-stage ovarian cancer; however, all randomized studies to date have been too small to answer this question reliably. METHODS: We performed a preplanned combined analysis of two parallel randomized clinical trials (International Collaborative Ovarian Neoplasm 1 [ICON1] and Adjuvant ChemoTherapy In Ovarian Neoplasm [ACTION]) in early-stage ovarian cancer that compared platinum-based adjuvant chemotherapy with observation following surgery. Between November 1990 and January 2000, 925 patients (477 in ICON1 and 448 in ACTION) who had surgery for early-stage ovarian cancer were randomly assigned to receive platinum-based adjuvant chemotherapy (n = 465) or observation (n = 460) until chemotherapy was indicated. Kaplan-Meier analysis was used to compare overall and recurrence-free survival by treatment allocation. In subgroup analyses of pretreatment age, tumor stage, histologic cell type, and differentiation grade, the differences in relative size of effect were tested using a chi-square test for interaction or a chi-square test for trend. All tests of statistical significance were two-sided. RESULTS: After a median follow-up of over 4 years, 245 patients had died or had a recurrence (ICON1: 133, ACTION: 112). Overall survival at 5 years was 82% in the chemotherapy arm and 74% in the observation arm (difference = 8% [95% confidence interval (CI) = 2% to 12%]; hazard ratio [HR] = 0.67, 95% CI = 0.50 to 0.90; P =.008). Recurrence-free survival at 5 years was also better in the adjuvant chemotherapy arm than it was in the observation arm (76% versus 65%, difference = 11% [95% CI = 5% to 16%]; HR = 0.64, 95% CI = 0.50 to 0.82; P =.001). Subgroup analyses provided no evidence of a difference in the size of effect of chemotherapy on survival in any pretreatment subcategory. CONCLUSIONS: Platinum-based adjuvant chemotherapy improved overall survival and recurrence-free survival at 5 years in this combined group of patients with early-stage ovarian cancer defined by the inclusion criteria of the ICON1 and ACTION trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Piccart, M. J. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.9.699 · Cited by 981
Trimbos, J. B., Vergote, I., Bolis, G., Vermorken, J. B., Mangioni, C., Madronal, C., Franchi, M., Tateo, S., Zanetta, G., Scarfone, G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.113 · Cited by 674
Muggia, F. M., Braly, P. S., Brady, M. F., Sutton, G., Niemann, T. H., Lentz, S. L., Alvarez, R. D., Kucera, P. R., & Small, J. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.106 · Cited by 601
Young, R. C., Walton, L. A., Ellenberg, S. S., Homesley, H. D., Wilbanks, G. D., Decker, D. G., Miller, A., Park, R., & Major, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199004123221501 · Cited by 583
ICON1 (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.125 · Cited by 287
Common Epithelial Cancer of the Ovary
Richardson, G. S., Scully, R. E., Nikrui, N., & Nelson, J. H. (1985) · New England Journal of Medicine · doi:10.1056/nejm198502143120706 · Cited by 204
Bolis, G., Colombo, N., Pecorelli, S., Torri, V., Marsoni, S., Bonazzi, C., Chiari, S., Favalli, G., Mangili, G., Presti, M., et al. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059355 · Cited by 169
Seltzer, V., Drukker, B. H., Gillespie, B. W., Gossfeld, L. M., Grigsby, P. W., Harvey, H. A., Hendricks, C. B., Hummel, S., Makuch, R. W., Monaco, G. P., et al. (1995) · JAMA · doi:10.1001/jama.273.6.491 · Cited by 154
The role of adjuvant therapy in Stage I ovarian cancer
Hreshchyshyn, M. M., Park, R. C., Blessing, J. A., et al. (1980) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(80)90024-1 · Cited by 142
Tropé, C., Kærn, J., Högberg, T., Abeler, V. M., Hagen, B., Kristensen, G. B., Onsrud, M., Pettersen, E. O., Rosenberg, P., Sandvei, R., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008399414923 · Cited by 108
Optimal surgical therapy in stage I and II ovarian malignancies
Piver, M. S. (1982) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(82)90522-3 · Cited by 11
Cited by
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa031644 · Cited by 2,335
Cannistra, S. A. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041842 · Cited by 2,129
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C., Elias, A. D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0016 · Cited by 1,584
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Metadata
- Authors
- (ICON1), I. C. O. N. 1., & European Organisation for Research and Treatment of Cancer Collaborators–Adjuvant ChemoTherapy In Ovarian Neoplasm (EORTC–ACTION)
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-01-15
- Volume
- 95
- Issue
- 2
- Pages
- 105-112
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W1513512556
- Cited by
- 443
- References
- 20
- FWCI
- 29.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.